华东医药：关于控股子公司获得美国FDA新药临床试验批准通知的公告

Core Viewpoint - East China Pharmaceutical announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd. (referred to as "Daor Bio"), has received approval from the U.S. Food and Drug Administration (FDA) for a clinical trial application for the drug DR10624, which targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1]. Company Summary - Daor Bio's clinical trial application for DR10624 has been approved by the FDA, allowing the company to conduct clinical trials in the United States [1]. - The drug is specifically aimed at treating MASLD, a condition related to metabolic dysfunction [1]. Industry Summary - The approval from the FDA signifies a potential advancement in the treatment options available for MASLD, which may impact the pharmaceutical industry focused on metabolic diseases [1]. - This development could enhance the competitive positioning of East China Pharmaceutical within the biopharmaceutical sector [1].